News

A grant of more than $400,000 has been awarded to a researcher who is searching for new ways to treat scleroderma, how the disease begins and progresses in the skin, and how it responds to treatments. The awardee is Karin Wuertz-Kozak, PhD, a professor in the biomedical engineering department…

Researchers have developed a 3D blood vessel-on-a-chip model to investigate problems with blood vessel growth in systemic sclerosis (SSc), a study reported. Immune-mediated changes to blood vessels is an early and central event in SSc development and usually occurs before the onset of fibrosis — the buildup of scar…

A protein called LMCD1 is present at higher levels in the lungs of patients with interstitial lung disease (ILD) linked to systemic sclerosis (SSc) than in healthy individuals, and may be a candidate target for the treatment of the disease, a small study suggests. Researchers found that the…

The active ingredient of EHP-101, a cannabidiol-derived medicine being developed by Emerald Health Pharmaceuticals (EHP), can set in motion a tissue’s response to low oxygen or hypoxia, which backs its use for  treating systemic sclerosis (SSc) and multiple sclerosis (MS), a study in cells and mice found.

People with systemic sclerosis (SSc) show higher levels of certain antibodies against the Epstein-Barr virus, which is suggestive of dormant viral infections becoming reactivated in these patients, a new study shows. The study, “Detection of Epstein–Barr virus in systemic sclerosis patients: A molecular and serological based…

The first two groups of patients have been enrolled in a Phase 2a clinical trial that’s testing the cannabidiol-derived medication EHP-101 in people with systemic scleroderma (SSc), the therapy’s developer Emerald Health Pharmaceuticals (EHP) announced. Interim results are expected next year, according to EHP. Participants are currently…

The release of CXCL10 — an inflammatory signaling molecule associated with a worse prognosis in scleroderma — from connective tissue cells and those lining blood vessel walls was significantly weakened with iloprost, a recent study reports. These findings showcase the added benefits of iloprost, commonly used to widen blood vessels…

The case of a 14-year-old boy with diabetes provided a starting point for a finding of juvenile systemic sclerosis (SSc): the limited joint mobility evident in the boy’s fingers can be an initial sign of underlying SSc, the report’s researchers suggested. Although “the coexistence of diabetes with juvenile systemic sclerosis…

Being male is linked with a higher risk of mortality among patients with scleroderma, irrespective of the type of autoantibody they carry, according to an analysis from two large databases. The study, “Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year…

The levels of certain metabolites — molecules that take part in metabolism — circulating in the blood may help differentiate pulmonary arterial hypertension (PAH) due to scleroderma (SSc-PAH) from idiopathic PAH, a new study shows. The “metabolic signature” correlated with worse disease severity in PAH tied to SSc.